I

IX Biopharma Ltd
SGX:42C

Watchlist Manager
IX Biopharma Ltd
SGX:42C
Watchlist
Price: 0.018 SGD Market Closed
Market Cap: 16m SGD

Gross Margin
IX Biopharma Ltd

18.4%
Current
44%
Average
48.6%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
18.4%
=
Gross Profit
1.3m
/
Revenue
7m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
SG
IX Biopharma Ltd
SGX:42C
15.9m SGD
18%
US
Eli Lilly and Co
NYSE:LLY
722.7B USD
82%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
US
Johnson & Johnson
NYSE:JNJ
393.4B USD
68%
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK
84%
CH
Roche Holding AG
SIX:ROG
204.4B CHF
74%
CH
Novartis AG
SIX:NOVN
182.4B CHF
76%
UK
AstraZeneca PLC
LSE:AZN
159.9B GBP
82%
US
Merck & Co Inc
NYSE:MRK
205.1B USD
78%
IE
Endo International PLC
LSE:0Y5F
183.8B USD
68%
US
Pfizer Inc
NYSE:PFE
139.8B USD
75%

IX Biopharma Ltd
Glance View

Market Cap
15.9m SGD
Industry
Pharmaceuticals

iX Biopharma Ltd. engages in the development and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. The firm is focused on the development and commercialization of therapies for diseases of the central nervous system using patent protected formulations for sublingual delivery. The company developed a patented drug delivery platform technology, WaferiX. WaferiX delivers drug sublingually via the mucosa for better absorption, faster onset of action and predictable effect. Its delivery platform is particularly useful for drug repurposing. The firm operates in two segments, namely Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical primary business activities are the development, manufacturing and sale of pharmaceutical and nutraceutical products. Nutraceutical primary business activities are the sale of nutraceutical products. The firm's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management.

42C Intrinsic Value
HIDDEN
Show
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
18.4%
=
Gross Profit
1.3m
/
Revenue
7m
What is the Gross Margin of IX Biopharma Ltd?

Based on IX Biopharma Ltd's most recent financial statements, the company has Gross Margin of 18.4%.

Back to Top